沙美特罗替卡松与噻托溴铵联合治疗稳定期COPD临床观察

Clinical observation on salmeterol-fluticasone combined with tiotropium bromide in treating stable COPD

目的观察对稳定期COPD患者予以沙美特罗替卡松与噻托溴铵联合治疗的临床效果。方法对2008年11月～2011年11月于本科治疗的120例稳定期COPD患者的临床资料进行回顾性分析,并将其随机分为A、B、C3组,每组40例。在常规治疗基础上,A组应用噻托溴铵与沙美特罗替卡松联合治疗;B组应用噻托溴铵治疗;C组应用沙美特罗替卡松治疗,3组均治疗6个月。结果经治疗后3组患者的肺功能及临床症状较治疗前均具有一定程度的改善,但同B、C组比较,A组改善更明显,差异均有统计学意义(P<0.05)。3组均出现轻微不良反应,但无因发生不良反应而提前终止治疗的患者。结论对稳定期COPD患者予以沙美特罗替卡松与噻托溴铵联合治疗,可显著改善患者的肺功能,且对减少临床并发症、提高患者生活质量均具有十分重要的意义,应予临床普遍推广。

Objective To observe the clinical effect of salmeterol-fluticasone combined with tiotropium bromide in treating stable COPD.Methods The clinical data of 120 cases of patients with stable COPD admitted in our department from November 2008 to November 2011 were analyzed retrospectively,they were randomly divided into group A,group B,and group C,with 40 cases in each group.On the basis of conventional therapy,group A were given salmeterol-fluticasone combined with tiotropium bromide in the treatment;Group B were given tiotropium bromide in the treatment;Group C were given salmeterol-fluticasone in the treatment,all the groups were treated for 6 months.Results Compared with treatment before,lung function and clinical symptoms of patients in three groups after treatment improved to a certain extent,but compared with group B and group C,group A improved more obvious,the differences were statistically significant （P 0.05）.There were a minor adverse reactions in three groups,but there was no case of early termination in treatment due to adverse reactions.Conclusion Salmeterol-fluticasone combined with tiotropium bromide in treating stable COPD can significantly improve pulmonary function of patients,and has great significance for reducing clinical complications,improving patients＇ quality of life,it should be promoted in clinical.